Lu, Gang

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 1,583

A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

Matyskiela, M. E., Lu, G., Ito, T., Pagarigan, B., Lu, C.-C., Miller, K., Fang, W., Wang, N.-Y., Nguyen, D., Houston, J., et al. (2016) · Nature

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 701

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology

Protein Degradation and InhibitorsPharmacological Effects and Toxicity Studies

Cited by 338

A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

Matyskiela, M. E., Zhang, W., Man, H.-W., Muller, G., Khambatta, G., Baculi, F., Hickman, M., LeBrun, L., Pagarigan, B., Carmel, G., et al. (2018) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 309

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 229

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 203

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia

Hansen, J. D., Correa, M., Alexander, M., Nagy, M., Huang, D., Sapienza, J., Lu, G., LeBrun, L. A., Cathers, B. E., Zhang, W., et al. (2021) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 159

Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex

Matyskiela, M. E., Clayton, T., Zheng, X., Mayne, C., Tran, E., Carpenter, A., Pagarigan, B., McDonald, J., Rolfe, M., Hamann, L. G., et al. (2020) · Nature Structural & Molecular Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 103

p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates

Nguyen, T. V., Li, J., Lu, C.-C. (., Mamrosh, J. L., Lu, G., Cathers, B. E., & Deshaies, R. J. (2017) · Proceedings of the National Academy of Sciences

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 85

UBE2G1 governs the destruction of cereblon neomorphic substrates

Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 78

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Lopez-Girona, A., Havens, C. G., Lu, G., Rychak, E., Mendy, D., Gaffney, B., Surka, C., Lu, C.-C., Matyskiela, M., Khambatta, G., et al. (2019) · Blood

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 25